Eli Lilly and Company (NYSE: LLY) is one of two pharmaceutical stocks behind the weight loss drug craze that has impacted the ...

Eli Lilly and Company’s LLY shares have risen 4.3% since it reported fourth-quarter results on Feb. 6. Lilly’s fourth-quarter ...

Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

We recently compiled a list of the 14 Best Large Cap Dividend Growth Stocks To Buy Now. In this article, we are going to take ...

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

A new study adds to a growing body of research suggesting a potential link between popular GLP-1 medications like Ozempic and vision loss.

The results add to evidence from animal studies and reports that people are finding the drugs helpful to manage cravings, not ...

New DTC platforms like LillyDirect and PfizerForAll are triggering a paradigm shift in how pharma companies connect with patients.

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...

Beyond treating diabetes and helping people lose weight, GLP-1s may also improve libido. But the reasons are as complex as ...

From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved ...